MiRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma.

ABSTRACT:

Background

Despite significant advancements in multiple myeloma (MM) therapy, the highly heterogenous treatment response hinders reliable prognosis and tailored therapeutics. Herein, we have studied the clinical utility of miRNAs in ameliorating patients' management.

Methods

miRNA-seq was performed in bone marrow CD138+ plasma cells (PCs) of 24 MM and smoldering MM (sMM) patients to analyze miRNAs profile. CD138+ and circulating miR-25 levels were quantified using in house RT-qPCR assays in our screening MM/sMM cohort (CD138+ plasma cells n = 167; subcohort of MM peripheral plasma samples n = 69). Two external datasets (Kryukov et al. cohort n = 149; MMRF CoMMpass study n = 760) served as institutional-independent validation cohorts. Patients' mortality and disease progressi

SUBMITTER: Papadimitriou MA 

PROVIDER: S-EPMC10080848 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature